0001209191-23-048252.txt : 20230905
0001209191-23-048252.hdr.sgml : 20230905
20230905200008
ACCESSION NUMBER: 0001209191-23-048252
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230831
FILED AS OF DATE: 20230905
DATE AS OF CHANGE: 20230905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JANKOWSKI JESS
CENTRAL INDEX KEY: 0001184478
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22333
FILM NUMBER: 231237512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NANOPHASE TECHNOLOGIES Corp
CENTRAL INDEX KEY: 0000883107
STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
IRS NUMBER: 363687863
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1319 MARQUETTE DRIVE
CITY: ROMEOVILLE
STATE: IL
ZIP: 60446
BUSINESS PHONE: 6303231200
MAIL ADDRESS:
STREET 1: 1319 MARQUETTE DRIVE
CITY: ROMEOVILLE
STATE: IL
ZIP: 60446
FORMER COMPANY:
FORMER CONFORMED NAME: NANOPHASE TECHNOLOGIES CORPORATION
DATE OF NAME CHANGE: 19970305
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-31
0
0000883107
NANOPHASE TECHNOLOGIES Corp
NANX
0001184478
JANKOWSKI JESS
1319 MARQUETTE DRIVE
ROMEOVILLE
IL
60446
1
1
0
0
President, CEO
0
Common Stock
1000
I
Spouse's IRA
Common Stock
59000
D
Common Stock
2023-08-31
4
M
0
2500
0.52
A
61500
D
Common Stock
2023-08-31
4
S
0
2500
1.00
D
59000
D
Common Stock
2023-09-01
4
M
0
2500
0.52
A
61500
D
Common Stock
2023-09-01
4
S
0
2500
1.00
D
59000
D
Common Stock
2023-09-05
4
M
0
2500
0.52
A
61500
D
Common Stock
2023-09-05
4
S
0
2500
1.014
D
59000
D
Common Stock (right to purchase)
0.52
2023-08-31
4
M
0
2500
0.52
D
2015-02-13
2024-02-13
Common Stock
80950
78450
D
Common Stock (right to purchase)
0.52
2023-09-01
4
M
0
2500
0.52
D
2015-02-13
2024-02-13
Common Stock
78450
75950
D
Common Stock (right to purchase)
0.52
2023-09-05
4
M
0
2500
0.52
D
2015-02-13
2024-02-13
Common Stock
75950
73450
D
Common Stock (right to purchase)
0.44
2016-02-18
2025-02-18
Common Stock
81000
81000
D
Common Stock (right to purchase)
0.42
2017-02-23
2026-02-23
Common Stock
69000
69000
D
Common Stock (right to purchase)
0.68
2018-02-21
2027-02-21
Common Stock
81000
81000
D
Common Stock (right to purchase)
0.82
2019-05-23
2028-05-23
Common Stock
90000
90000
D
Common Stock (right to purchase)
0.51
2020-05-22
2029-05-22
Common Stock
16500
16500
D
Common Stock (right to purchase)
0.45
2021-06-18
2027-06-18
Common Stock
90000
90000
D
Common Stock (right to purchase)
4.17
2022-12-28
2028-12-28
Common Stock
90000
90000
D
Common Stock (right to purchase)
1.165
2023-12-20
2029-12-20
Common Stock
72000
72000
D
These stock options are set to expire on 02/13/2024. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
If not sold through a 10b5-1 Plan, Nanophase trading blackout periods run from the 25th of the last day of any given quarter until 3 days after earnings are released. In example, for options expiring during the 1st quarter of any given year, trading would be prohibited from December 25th of the prior year, through the release of annual earnings plus 3 business days. Typically, this would reopen trading in early-to-mid March, through March 24th. The next blackout period would begin on March 25th, etc. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders.
These stock options are set to expire on 02/13/2024. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors.
Subject to certain restrictions, beginning on this date, options vest in three equal installments.
Subject to certain restrictions, beginning on this date, the options vest in three equal annual installments.
Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker to avoid the loss of these stock option rights. His goal is to have this broker sell shares from this grant, under fixed guidelines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Given the quantity of shares involved relative to daily trading volume, the limited amount of open trading days available due to trading blackout periods, and looming stock option expirations, Mr. Jankowski established a 10b5-1 Plan to avoid the loss of these rights in a way intended to minimize the impact on Nanophase shareholders.
Jess A. Jankowski
2023-09-05